Business ❯ Pharmaceuticals ❯ Biotechnology

Drug Development

Obesity Treatments Acquisitions Clinical Trials Molecular Glue Degraders Clinical Research Prostate Cancer Therapeutics Myelofibrosis Collaboration Cystic Fibrosis Treatments Autoimmune Diseases FDA Regulations Licensing Agreements Evotec SE Collaboration Agreements Market Potential Bispecific Antibodies Blood Coagulation Treatments RNA Technology Rare Diseases Monte Rosa Therapeutics Market Access Efzofitimod Artificial Intelligence Generative AI Monoclonal Antibodies Regulatory Affairs CAR T-cell Therapy Weight Loss Drugs Oral Biologics

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

The decision introduces a protein‑degrading drug class to oncology practice.

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside

Lilly, Repertoire Strike Up-to-$1.93 Billion Autoimmune Drug Pact

Insilico, Qilu Strike Near-$120 Million AI Drug Discovery Pact for Cardiometabolic Therapies

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

Telix Securities Suit Advances as Investor Firms Push Lead-Plaintiff Bids Before Jan. 9 Deadline

Vertex Tops Q3 Estimates on CF Franchise as New Drugs Miss and Outlook Edges Higher

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

Rani Therapeutics and Chugai Sign Oral Biologics Collaboration Worth Up to $1.085 Billion

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

CSL Secures VarmX Acquisition Option, Funding Phase 3 of Factor Xa Reversal Drug

Vertex Halts VX-993 Acute Pain Program After Phase 2 Trial Failure

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy

Cidara’s CD388 Antiviral Achieves Up to 76% Flu Protection in Phase 2b Trial

Pfizer Secures $6 Billion Licensing Deal for Chinese Cancer Drug SSGJ-707